25th Annual Meeting of the European Charcot Foundation, November 30 till December 2, 2017, Baveno (IT)
 

The Board of the European Charcot Foundation is proud to present the preliminary program of the 25th Anniversary edition of its Annual Meeting.

More detailed information on the faculty of the different topics will be available soon.

Please note this is a preliminary program, small changes may occur.

Thursday November 30, 2017
10:10 - 10:35Welcome Coffee
10:35 - 11:35Satellite Symposium EXCEMED - Excellence in Medical Education
Today's choices for tomorrow’s reality

Introduction and welcome
Giancarlo Comi

Immunological modes of action and clinical efficacy of emerging MS treatments
Heinz Wiendl

High efficacy treatments in the management of patients
Klaus Schmierer

Tackling clinical decision making and conclusions
Gavin Giovannoni
11:35 - 11:45Break
11:45 - 12:45Industry-sponsored Satellite Symposium
Merck Satellite Symposium

Cladribine Tablets in MS: providing durable efficacy and a reduced monitoring burden through a unique MoA

Welcome and objectives
Hans-Peter Hartung

Cladribine Tablets: an innovative treatment that provides durable efficacy in MS
Oscar Fernandez

Cladribine Tablets: Safety and tolerability profile and implication for monitoring
Antonio Uccelli 

Q&A - Panel discussion 

Wrap up and Close
Hans-Peter Hartung
12:45 - 13:15Light Lunch
13:15 - 14:15XXV ECF Lecture
Comi Giancarlo - Chair
  
History of the Foundation and what has changed in these 25 years in Multiple Sclerosis
van Eikema Hommes Otto R.
14:15 - 16:00SESSION I: ABOUT THE CAUSES OF THE DISEASE
Ebers George - Chair

Lecture 1: Epidemiology
Scalfari Antonio

Lecture 2: Genetic
Sawcer Stephen

Lecture 3: Environmental factors
Ascherio Alberto

Lecture 4: Mucosal biopsy shows immunologic changes of the colon in patients with early MS
Moser Adrian Mathias
16:00 - 16:30Coffee Break and Poster Viewing
16:30 - 18:00SESSION II: THE CHANGING LANDSCAPE OF BASIC STUDIES
Freedman Mark - Chair

Lecture 1: Pathology
Brück Wolfgang

Lecture 2: From a T cell story to a complex immune mechanism
Wekerle Hartmut

Lecture 3: Pathophysiological mechanism in the various phases of the disease
Lassmann Hans

Lecture 4: Intrathecal inflammatory profile and cortical damage can stratify MS patients
Magliozzi Roberta
18:00 - 18:15Coffee Break
18:15 - 19:15Industry-sponsored Satellite Symposium
Sanofi Genzyme Satellite Symposium

Evolving landscapes in MS research and clinical practice - From traditional to novel measures

Welcome and Introduction 
Nicola De Stefano

Novel clinical measures to assess MS-related parameters and treatment efficacy
Ralf Linker

New insights into patient-reported outcomes in MS 
Iris-Katharina Penner

Q&A 
19:15 - 20:15Welcome Cocktail

Friday December 1, 2017
08:30 - 10:15SESSION III: HOW THE MS FACE HAS CHANGED
Fujihara Kazuo - Chair

Lecture 1: Diagnostic criteria a never ending story
Edan Gilles

Lecture 2: Classification of disease courses
Cohen Jeffrey

Lecture 3: At the border of MS (NMOSD, ADEM, anti MOG)
Palace Jacqueline

Lecture 4: Distinguishing MOG antibody disease from childhood MS
Hacohen Yael
10:15 - 11:15Coffee Break and Poster Viewing
11:15 - 13:00SESSION IV: HOW TO MONITOR DISEASE EVOLUTION AND TREATMENT
Miller Ariel - Chair

Lecture 1: Role of brain MRI
Fazekas Franz

Lecture 2: Role of spiral cord MRI
Filippi Massimo

Lecture 3: Body fluids
Khalil Michael

Lecture 4: Neurophysiological biomarkers included OCT and more
Leocani Letizia
13:00 - 14:00Lunch
14:00 - 15:45SESSION V: CLINICAL TRIALS AND OUTCOME MEASURES
Boyko Alexey - Chair

Lecture 1: Clinical trial designs
Kappos Ludwig

Lecture 2: Outcome measures
Hobart Jeremy

Lecture 3: Patient reported outcomes
Solari Alessandra

Lecture 4: Clinical trials in pediatric MS
Ghezzi Angelo
15:45 - 16:15Coffee Break
16:15 - 18:00SESSION VI: FROM NO TREATMENT TO A COMPLEX TREATMENT ARMAMENTARIUM
Selmaj Krzysztof - Chair

Lecture 1: The evolution of treatment for relapsing MS
Hartung Hans-Peter

Lecture 2: Do we really hit the phenomenon of progression with available treatment
Montalban Xavier

Lecture 3: Efficacy and effectiveness
Trojano Maria

Lecture 4: Risk minimization in MS treatment
Uitdehaag Bernard M. J.
18:00 - 18:15Coffee Break
18:15 - 19:15Industry-sponsored Satellite Symposium
Celgene Satellite Symposium

The evolution of MS Treatment: S1P Modulators; reviewing ongoing clinical development programs

Welcome and Introductions
Maria Pia Amato

Exploring the Underlying Mechanism of Disease
Ludwig Kappos

S1P Modulators and Phase 2 & 3 Trials
Hans-Peter Hartung

Meeting Close 
Maria Pia Amato 

Saturday December 2, 2017
07:15 - 07:30Light Breakfast
07:30 - 08:30Satellite Symposium MS in the 21st Century

Welcome and Introductions
Dawn Langdon

The digital healthcare revolution: A journey towards patient engagement
Gavin Giovannoni

Debate: Patient power – do the benefits always outweigh the risks?
Gavin Giovannoni & David Yeandle 
Moderated by: Dawn Langdon

Talking the same language: Progress and challenges for joint communication in MS
Peter Rieckmann & David Yeandle

Q&A 
Dawn Langdon

Close
Dawn Langdon
08:30 - 10:15SESSION VII: ENHANCING RECOVERY AND SYMPTOMATIC TREATMENT
Thompson Alan - Chair

Lecture 1: Molecular mechanism to enhance recovery
Lubetzki Catherine

Lecture 2: Where we are with physical and mental exercise
Kesselring Jürg

Lecture 3: Symptomatic treatment
Sorensen Per Soelberg

Lecture 4: Regenerative approaches for demyelinating diseases
Simons Mikael
10:15 - 10:45Coffee Break
10:45 - 12:00SESSION VIII: TRANSLATING SCIENCE INTO PATIENT MANAGEMENT
Cristiano Edgardo - Chair

Lecture 1: How MS care is changed in Europe
Fernandez Oscar

Lecture 2: Dealing with increasing economic constraints
Giovannoni Gavin

Lecture 3: Multistakeholder initiative
Vermersch Patrick

Lecture 4: MS center organization
Comi Giancarlo
12:00 - 12:30Young Investigator Awards
12:30 - 13:00Closing Remarks
13:00 - 14:00Lunch